Related Experiment Video
Updated: Jan 7, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Polydopamine-encapsulated modified Pulsatilla decoction: a strategy to enhance ulcerative colitis therapy
Ying-Jian Chen1, Cheng-Qi Li2, Chang Liu2
1Department of Internal Medicine, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, 215003, China.
Background:
In Traditional Chinese Medicine (TCM), ulcerative colitis (UC) is often categorized as "protracted dysentery." Pulsatilla Decoction has been reported to exert therapeutic benefits in patients with protracted dysentery. To potentially improve therapeutic outcomes in ulcerative colitis, we prepared a modified Pulsatilla Decoction (MPD). Preliminary clinical observations have suggested that MPD may alleviate symptoms in UC patients. However, rectal enema of MPD is often limited by suboptimal patient compliance and relatively short colonic retention. These limitations underscore the need for new TCM formulations. In this study, we encapsulated MPD within polydopamine (PDA) nanoparticles to prolong colonic residence and evaluate therapeutic effects in a UC model.
Methods:
First, PDA@MPD was prepared by encapsulating MPD with PDA. Fourier transform infrared spectroscopy (FT-IR) and other analytical instruments characterized its structure, morphology, and particle size. Drug release property was evaluated by UV-vis spectrophotometry. Subsequently, MPD active components were labeled with Fluorescein isothiocyanate (FITC); PDA@FITC-MPD was prepared similarly and administered orally to mice. In vivo fluorescence imaging tracked retention time and location in the gastrointestinal tract. Finally, the UC model was induced with 3% DSS. After 7 days of PDA@MPD treatment, therapeutic efficacy was assessed via disease activity index (DAI), colon length, histopathology, Western blot, quantitative real-time PCR (qRT-PCR), and ELISA.
Results:
MPD was encapsulated by PDA. Relative to MPD, PDA@MPD showed a prolonged colonic retention time and modest improvements in colonic damage scores and inflammatory markers in DSS-induced UC mice. These changes were associated with up-regulation of tight-junction proteins (Occludin, ZO-1) and down-regulation of pro-inflammatory cytokines (IL-1β, TNF-α) in the PDA@MPD group.
Conclusion:
This study indicates that PDA@MPD prolongs colonic retention and is associated with modest improvements in DSS-induced colonic damage and inflammation in mice. These findings may offer a proof-of-concept for exploring polydopamine-based delivery systems in TCM formulations.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
08:34Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents